Australian psychotropic medicine, biotech, research & development company, MYND BIO Pty Ltd are proud to announce the official signing of a lucrative distribution agreement with a leading pharmaceutical company in the USA.
The management team at MYND BIO are optimistic about the opportunities this opens for the business from a revenue and exposure into the extensive USA market standpoint and are moving forward into the next phase of the business now.
MYND BIO have their sights set on being one of the worlds largest suppliers of pharmaceutical grade psychedelic drugs for the use in the treatment of mental health. They have successfully secured some of the leading global specialists in the scientific & pharmacological arena to work on developing, manufacturing and distribution of their products.
They have already forged some key alliances with partner organisations that enhance their structure and operations and this latest agreement with the Pharmaceutical organisation in the USA closes the distribution element.
MYND BIO are excited to be embarking on this next phase.
